CoraLite® Plus 488-conjugated Apolipoprotein AI Monoclonal antibody

• 

  IF Staining of HepG2 using CL488-66206

  Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using CL488-66206 (Apolipoprotein AI antibody) at dilution of 1:100.

• 

  IF Staining of L02 using CL488-66206

  Immunofluorescent analysis of (-20°C Ethanol) fixed L02 cells using CoraLite® Plus 488-conjugated Apolipoprotein AI antibody (CL488-66206, Clone: 1C9G5 ) at dilution of 1:100, CL594-Phalloidin (red).

Apolipoprotein AI Monoclonal Antibody for IF/ICC

Cat No. CL488-66206

Clone No.1C9G5

Host / Isotype

Mouse / IgG2b

Reactivity

human, mouse

Applications

IF/ICC

Synonyms

Apo AI, ApoA I, APOA1, apolipoprotein A I, Apolipoprotein A1

---

Tested Applications

• Positive IF/ICC detected in: HepG2 cells, L02 cells

Recommended dilution

• Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

CL488-66206 targets Apolipoprotein AI in IF/ICC applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Host / Isotype: Mouse / IgG2b
• Class: Monoclonal
• Type: Antibody
• Immunogen: Apolipoprotein AI fusion protein Ag21920
• Full Name: apolipoprotein A-I
• Calculated Molecular Weight: 31 kDa
• Observed Molecular Weight: 26-28 kDa
• GenBank Accession Number: BC005380
• Gene Symbol: APOA1
• Gene ID (NCBI): 335
• RRID: AB_2883284
• Conjugate: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission Maxima Wavelengths: 493 nm / 522 nm
• Form: Liquid
• Purification Method: Protein A purification
• UNIPROT ID: P02647
• Storage Buffer: PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3.
• Storage Conditions: Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage.

Background Information

ApoA1 is a major protein component of high density lipoproteins (HDL) which is associated with reversed cholesterol transport, lipid/cholesterol binding, lecithin/cholesterol acyltransferase (LCAT) activation and specific receptors binding. It is synthesized in the liver and small intestine. Defects of ApoA1 cause low HDL level and systemic non-neuropathic amyloidosis. Serum concentration of ApoA1 is inversely related to the risk of developing atherosclerosis. This antibody was generated against the C-terminal region of human ApoA1.